Shell Asset Management CO Sage Therapeutics, Inc. Transaction History

Shell Asset Management CO

$2.27 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	SELL	$32.2 - $43.61 $50,103 - $67,857	-1,556 Reduced 17.36%	7,405 $282,000
Q3 2022 Nov 14, 2022	SELL	$32.28 - $43.27 $75,793 - $101,597	-2,348 Reduced 20.76%	8,961 $351,000
Q2 2022 Aug 09, 2022	BUY	$27.52 - $37.99 $495 - $683	18 Added 0.16%	11,309 $365,000
Q1 2022 May 04, 2022	SELL	$30.71 - $45.71 $51,347 - $76,427	-1,672 Reduced 12.9%	11,291 $374,000
Q4 2021 Feb 09, 2022	BUY	$37.06 - $47.11 $100,506 - $127,762	2,712 Added 26.46%	12,963 $551,000
Q3 2021 Nov 04, 2021	SELL	$40.26 - $57.37 $17,714 - $25,242	-440 Reduced 4.12%	10,251 $454,000
Q2 2021 Aug 12, 2021	BUY	$54.88 - $79.29 $31,830 - $45,988	580 Added 5.74%	10,691 $607,000
Q1 2021 May 10, 2021	BUY	$70.65 - $96.76 $404,329 - $553,757	5,723 Added 130.42%	10,111 $757,000
Q2 2020 Aug 10, 2020	SELL	$25.95 - $43.15 $2,205 - $3,667	-85 Reduced 1.9%	4,388 $182,000
Q1 2020 May 11, 2020	SELL	$26.15 - $77.24 $1,830 - $5,406	-70 Reduced 1.54%	4,473 $128,000
Q4 2019 Feb 13, 2020	SELL	$60.18 - $154.77 $7,943 - $20,429	-132 Reduced 2.82%	4,543 $328,000
Q3 2019 Nov 12, 2019	SELL	$140.29 - $189.96 $5,611 - $7,598	-40 Reduced 0.85%	4,675 $656,000
Q2 2019 Aug 12, 2019	SELL	$157.85 - $183.09 $17,205 - $19,956	-109 Reduced 2.26%	4,715 $863,000
Q1 2019 May 09, 2019	BUY	$89.33 - $163.65 $214,749 - $393,414	2,404 Added 99.34%	4,824 $767,000
Q4 2018 Feb 13, 2019	SELL	$81.94 - $139.71 $16,388 - $27,942	-200 Reduced 7.63%	2,420 $232,000
Q2 2018 Aug 10, 2018	SELL	$140.36 - $175.76 $14,036 - $17,576	-100 Reduced 3.68%	2,620 $410,000
Q1 2018 May 14, 2018	BUY	$152.15 - $192.33 $413,848 - $523,137	2,720 New	2,720 $438,000

Others Institutions Holding SAGE

# of Institutions

198

Shares Held

46.5M

Call Options Held

402K

Put Options Held

209K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.

Account